Ozempic
The Ozempic Price War: How a 71% Medicare Discount is Reshaping Healthcare Finance
A landmark 71% Medicare price cut on Ozempic and Wegovy signals a major shift in healthcare finance, impacting investors, the economy, and Big Pharma.
The Hundred-Billion-Dollar Pill: Inside Pfizer’s High-Stakes Gamble to Conquer the Weight-Loss Market
Pfizer is betting billions on an oral weight-loss pill to challenge Novo Nordisk and Eli Lilly’s injectable dominance in a market poised to hit $100B.
The Ozempic Economy: How a Weight-Loss Shot is Reshaping Markets and Killing the Business Lunch
A new class of weight-loss drugs is shaking up the economy, impacting the stock market and threatening the future of the traditional business lunch.